Zobrazeno 1 - 10
of 1 802
pro vyhledávání: '"Ribas Antoni"'
Autor:
Purbey, Prabhat K., Seo, Joowon, Paul, Manash K., Iwamoto, Keisuke S., Daly, Allison E., Feng, An-Chieh, Champhekar, Ameya S., Langerman, Justin, Campbell, Katie M., Schaue, Dörthe, McBride, William H., Dubinett, Steven M., Ribas, Antoni, Smale, Stephen T., Scumpia, Philip O.
Publikováno v:
In Cell Reports 25 June 2024 43(6)
Autor:
Katz, Sanford, Ciuba, Doug, Ribas, Antoni, Shelach, Noa, Zelinger, Galit, Barrow, Briana, Corn, Benjamin W.
Publikováno v:
In JAAD International June 2024 15:62-68
Autor:
Chen, Daniel G., Xie, Jingyi, Choi, Jongchan, Ng, Rachel H., Zhang, Rongyu, Li, Sarah, Edmark, Rick, Zheng, Hong, Solomon, Ben, Campbell, Katie M., Medina, Egmidio, Ribas, Antoni, Khatri, Purvesh, Lanier, Lewis L., Mease, Philip J., Goldman, Jason D., Su, Yapeng, Heath, James R.
Publikováno v:
In Cell Reports 26 March 2024 43(3)
Autor:
Ertl, Carolin, Ruf, Theresa, Mentzer, Dirk, Kong, Mingzi, Kramer, Rafaela, Bergwelt-Baildon, Michael von, Subklewe, Marion, Tomsitz, Dirk, Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen, Lebbé, Celeste, Long, Georgina V., McArthur, Grant, Neilan, Tomas G., Ribas, Antoni, Robert, Caroline, Schadendorf, Dirk, Zimmer, Lisa, Eigentler, Thomas, Grabbe, Stephan, Forschner, Andrea, Kähler, Katharina C., Milani, Valeria, Pföhler, Claudia, Hassel, Jessica, Gutzmer, Ralf, Loquai, Carmen, Routy, Bertrand, Furness, Andrew J.S., Blank, Christian, Wolchok, Jedd D., French, Lars E., Hauschild, Axel, Heinzerling, Lucie
Publikováno v:
In European Journal of Cancer March 2024 199
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Autor:
Brahmer, Julie R., Long, Georgina V., Hamid, Omid, Garon, Edward B., Herbst, Roy S., Andre, Thierry, Armand, Philippe, Bajorin, Dean, Bellmunt, Joaquim, Burtness, Barbara, Choueiri, Toni K., Cohen, Ezra E.W., Diaz, Luis A., Jr, Shitara, Kohei, Kulkarni, Girish, McDermott, David, Shah, Manish, Tabernero, Josep, Vogel, Arndt, Zinzani, Pier Luigi, Jafari, Niusha, Bird, Steven, Snyder, Ellen, Gause, Christine, Bracco, Oswaldo L., Pietanza, M. Catherine, Gruber, Todd, Ribas, Antoni
Publikováno v:
In European Journal of Cancer March 2024 199
Autor:
Gentilcore Giusy, Madonna Gabriele, Mozzillo Nicola, Ribas Antoni, Cossu Antonio, Palmieri Giuseppe, Ascierto Paolo A
Publikováno v:
BMC Cancer, Vol 13, Iss 1, p 17 (2013)
Abstract Background Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in
Externí odkaz:
https://doaj.org/article/00c3a3a755b34f338a7149a6d5b5d3df
Autor:
Ribas Antoni, Chesney Jason A, Gordon Michael S, Abernethy Amy P, Logan Theodore F, Lawson David H, Chmielowksi Bartosz, Glaspy John A, Lewis Karl, Huang Bo, Wang Erjian, Hsyu Poe-Hirr, Gomez-Navarro Jesus, Gerhardt Diana, Marshall Margaret A, Gonzalez Rene
Publikováno v:
Journal of Translational Medicine, Vol 10, Iss 1, p 236 (2012)
Abstract Background CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized clinical trials with overall
Externí odkaz:
https://doaj.org/article/77e605fdeb0e419fa7f1fd10b3d924a9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ascierto Paolo A, Grimaldi Antonio M, Curti Brendan, Faries Mark B, Ferrone Soldano, Flaherty Keith, Fox Bernard A, Gajewski Thomas F, Gershenwald Jeffrey E, Gogas Helen, Grossmann Kenneth, Hauschild Axel, Hodi F, Kefford Richard, Kirkwood John M, Leachmann Sancy, Maio Michele, Marais Richard, Palmieri Giuseppe, Morton Donald L, Ribas Antoni, Stroncek David F, Stewart Rodney, Wang Ena, Mozzillo Nicola, Marincola Franco M
Publikováno v:
Journal of Translational Medicine, Vol 10, Iss 1, p 83 (2012)
Abstract After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunization. After the first congress in
Externí odkaz:
https://doaj.org/article/b98e530d14134cbcb527b732b8619d7c
Autor:
von Euw Erika, Atefi Mohammad, Attar Narsis, Chu Connie, Zachariah Sybil, Burgess Barry L, Mok Stephen, Ng Charles, Wong Deborah JL, Chmielowski Bartosz, Lichter David I, Koya Richard C, McCannel Tara A, Izmailova Elena, Ribas Antoni
Publikováno v:
Molecular Cancer, Vol 11, Iss 1, p 22 (2012)
Abstract Background TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2. Methods The growth inhibitory effects of TAK733 were assessed in a panel of 27 cutaneous and five uveal melanoma cell lines genotyped for dri
Externí odkaz:
https://doaj.org/article/ce5029448ceb46ae8246771e3b3ee94f